A less intense treatment before surgery for early HER2-positive breast cancer
Part of Cancer clinical trials.
This trial tests whether a less intense treatment before surgery works as well as the standard approach for early-stage HER2-positive breast cancer. It aims to reduce side effects while still being effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive invasive breast cancer, which means your cancer cells have too much of a protein called HER2 that helps them grow.
- Your tumor is stage T2N0M0, meaning it is between 2 and 5 centimeters and has not spread to lymph nodes or other parts of the body.
- You have not had chemotherapy, hormone therapy, targeted therapy, or radiation for this breast cancer before.
- You do not have severe, uncontrolled medical conditions that would make chemotherapy unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial tests whether giving Herceptin for a shorter time after chemotherapy works as well as the usual longer treatment for early-stage HER2-positive breast cancer. It aims to reduce side effects and treatment burden while keeping the same benefits.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.